 | | | | (Corrects Aug. 9 story to show study points to overall survival and not progression free survival in first paragraph) | | |
| | | AstraZeneca Plc said on Wednesday it had received marketing authorization from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer. | | |
| | | Drugmaker Polyphor is hiring new managers and shifting focus after a trial of its top antibiotic hopeful proved too dangerous to continue, the Swiss company said on Wednesday. | | |
| | | A U.S. judge on Tuesday rejected efforts by major drugmakers, pharmacies and distributors to dismiss claims that they caused the nation's opioid crisis, clearing the way for a scheduled landmark trial even as he pushes for a nationwide settlement. | | |
| | | Novartis AG's gene therapy for blindness, Luxturna, is recommended for use on England's public health service, the country's healthcare cost-effectiveness watchdog NICE said on Tuesday. | | |
| | | (Reuters Health) - Exercise can do more to lower the risk of premature death for patients with cardiovascular disease than for healthy people, a new study suggests. | | |
| | | NEW YORK (Reuters Health) - Women with a high risk of developing breast cancer can lower that risk by taking certain medications, according to updated recommendations from the US Preventive Services Task Force (USPSTF). | | |
| | | (Reuters Health) - A growing number of extremely tiny newborns are being sent home from the hospital with human milk for feedings when their mothers don't produce enough milk to meet their nutritional needs, a U.S. study suggests. | | |
| | | (Reuters Health) - Consumption of soft drinks, whether they're sweetened with sugar or artificial sweeteners, may raise the risk of premature death, new research suggests. | | |
| | | Cancer has overtaken heart disease as the leading cause of death in wealthy countries and could become the world's biggest killer within just a few decades if current trends persist, researchers said on Tuesday. | | |
| | | Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments. | | |
|
| |
